Theralase AnnouncesTwo Patients Free of Bladder Cancer After Single Treatment in Ph Ib Study

Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) reported on 1/30/19 that patient six, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study ("Study"), has demonstrated no tumor recurrence or presence of disease at the 270 day clinical and cystoscopy assessment.